Rothblatt Files Form 144 for 119,410 Shares (~$71.5M) After 608,000 Sold in 3 Months
UTHR sits 39% above its 52-week low of $430.02.
Summary
CEO Martine Rothblatt noticed the proposed sale of 119,410 option-derived shares worth about $71.5M, on top of 608,000 shares already sold for $319.2M over the past three months under a pre-arranged 10b5-1 plan.
Key Events · Ownership and Investor Activity · UTHR
-
CEO Notices 119,410-Share Sale
Rothblatt filed a Form 144 for 119,410 common shares with an aggregate market value of $71,493,155.20, acquired the same day via exercise of stock options from the issuer.
-
608,000 Shares Already Sold
Table II shows 608,000 shares sold over the past three months for gross proceeds of $319,182,639.70 — about 1.4% of the 42,890,692 shares outstanding (608000/42890692 = 1.42%).
-
Pre-Planned 10b5-1 Program
Sales run under a 10b5-1 plan adopted 11/21/2025, so execution is scheduled rather than discretionary; the notice is dated 11/02/2026.
-
Buyback Offsets Supply
The company completed a $477.6M accelerated share repurchase in September and authorized a new $2 billion repurchase program through October 21, 2027 on 2026-10-22.
Analysis · UTHR · Life Sciences
This is the largest single tranche in a steady, pre-planned liquidation by CEO and founder Martine Rothblatt. The notice covers 119,410 shares acquired through an option exercise on 11/02/2026 and proposed for sale at an aggregate market value of $71,493,155.20 — about 12.6 times the 9,500-share sale reported minutes earlier. More telling is Table II: 608,000 shares have already been sold over the past three months for $319,182,639.70, roughly 1.4% of the 42,890,692 shares outstanding. Because the sales run under a 10b5-1 plan adopted 11/21/2025, timing is mechanical rather than a discretionary call on the stock. Meanwhile, the company is buying back stock — a $477.6M accelerated share repurchase in September and a new $2 billion authorization on 2026-10-22. The supply is real but scheduled; the offsetting buyback is the counterweight.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTHR was trading at $596.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.6B. The 52-week trading range was $430.02 to $609.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.